L-Bupivacaine
Thoracic Neoplasm
Guy's and St Thomas' NHS Foundation TrustSmall moleculePhase 2/3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
13 Active assets in the Thoracic Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Fundación GECP | Phase 3 | BB |
Pralsetinib, trans- Hoffmann-La Roche | Phase 3 | B |
CIS-DIAMMINEDICHLOROPLATINUM II Nanfang Hospital, Southern Medical University | Phase 3 | B |
Pembrolizumab Amgen | Phase 3 | B |
Gefetinib Chinese Society of Lung Cancer | Phase 3 | B |
View all 24 →
Same molecule, other indications
L-Bupivacaine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →